Real-World Evidence in Drug Approval: Moving Toward Greater Regulatory Clarity
药物审批中的真实世界证据：迈向更高的监管清晰度- 生物通
Summary
The FDA emphasizes the growing importance of utilizing Real-World Data (RWD) in drug approval processes, demanding higher transparency and standardization. Adherence to international standards like CDISC and HL7 FHIR is crucial, impacting global healthcare IT practices including Japan.
Details
This article discusses the evolving landscape of using Real-World Evidence (RWE) in pharmaceutical drug approval. The FDA increasingly requires RWD—beyond traditional clinical trial data—for submissions, raising regulatory bar. Technically, standardizing RWD collection and analysis is critical. The FDA strongly recommends adherence to industry standards like CDISC and international healthcare interoperability specifications such as HL7 FHIR. This ensures seamless data sharing across different institutions and systems, enabling the construction of reliable RWE. Furthermore, compliance requires robust governance (e.g., IRB/Ethics Committee approval) and privacy protection. This trend provides crucial insights for Japanese medical institutions and pharmaceutical companies to strengthen their capacity for building RWE based on international standards, supporting global drug development strategies.
Original content copyright by respective publishers